FrancophonIA/ELRC3.0 huggingface dataset:
English: Kyntheum should not be injected into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.
Croatian: prekrivena modricama, crvena, tvrda, debela, ljuskasta ili zahvaćena psorijazom.
English: Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal ideation, anxiety, or other mood changes, and they should contact their healthcare provider if such events occur.
Croatian: suicidalnih misli, anksioznosti ili drugih promjena raspoloženja te da obavijeste svog liječnika u slučaju pojave takvih događaja.
English: For a 3-fold increase in SC brodalumab dose from 70 to 210 mg, the steady-state serum brodalumab Cmax and AUC0-t increased approximately 18- and 25-fold, respectively.
Croatian: Pri trostrukom povećanju doze SC brodalumaba sa 70 na 210 mg,
English: • candida (fungal) infection in the mouth, throat or genitals • discharge from the eye with itching, redness and swelling (conjunctivitis).
Croatian: • iscjedak iz oka sa svrbežom, crvenilom i oticanjem (konjunktivitis)
English: Elevated levels of IL-17A, IL-17C and IL-17F gene expression are found in psoriatic plaques.
Croatian: U psorijatičnim plakovima pronađene su povišene razine ekspresije gena IL-17A, IL-17C i IL-17F.
English: Patients should be instructed to inject the full amount of Kyntheum according to the instructions provided in the package leaflet.
Croatian: Bolesnike je potrebno uputiti da injiciraju cijelu količinu lijeka
English: However, brodalumab concentrations below LLOQ (Lower Limit of Quantification) were associated with IL-17 receptor occupancy up to 81%.
Croatian: No koncentracije brodalumaba ispod donjeg limita kvantifikacije (engl.
English: Make sure the medicine in the syringe is clear to slightly pearly and colourless to slightly yellow.
Croatian: Provjerite je li lijek u štrcaljki bistar do blago biseran te bezbojan do žućkast.
English: Using your Kyntheum pre-filled syringe
Croatian: Primjena napunjene štrcaljke lijeka Kyntheum
English: LEO Pharma Sp. z o.o.
Croatian: LEO Pharma A/S
English: • your outer area of upper arm.
Croatian: • stražnji dio nadlaktice.
English: • Do not inject into areas where the skin is tender, bruised red, or hard.
Croatian: • Nemojte injicirati lijek u područja na kojima je koža osjetljiva na dodir, prekrivena modricama,
English: Water for injections
Croatian: Otopina za injekciju (injekcija).
English: Package leaflet: Information for the patient Kyntheum 210 mg solution for injection in pre-filled syringe brodalumab This medicine is subject to additional monitoring.
Croatian: Uputa o lijeku: Informacije za bolesnika Kyntheum 210 mg otopina za injekciju u napunjenoj štrcaljki brodalumab
English: • Do not twist or bend the grey needle cap. • Do not put the grey needle cap back onto the syringe.
Croatian: • Nemojte ponovno stavljati sivi zatvarač igle na štrcaljku.
English: However, there were no proliferative changes in cynomolgus monkeys administered weekly subcutaneous doses of brodalumab at 90 mg/kg for 6 months (AUC exposure 47-fold higher than in human patients receiving Kyntheum 210 mg every 2 weeks).
Croatian: No primjena brodalumaba u supkutanim dozama od 90 mg/kg jednom tjedno tijekom 6 mjeseci u makaki majmuna nije izazvala promjene u proliferaciji (AUC izloženost 47 puta veća nego u ljudskih bolesnika koji primaju
English: • any part appears cracked or broken.
Croatian: • postoje napukline ili oštećenja.
English: Immunogenicity
Croatian: Imunizacije
English: For subcutaneous use
Croatian: Za potkožnu primjenu
English: Kyntheum pre-filled syringe can only be used once.
Croatian: Jedna napunjena štrcaljka lijeka Kyntheum namijenjena je isključivo za jednokratnu uporabu.
English: Patients randomised to Kyntheum in the induction phase received 210 mg or 140 mg at Week 0 (day 1), Week 1, and Week 2 followed by same dose every 2 weeks.
Croatian: Kyntheum primali su u indukcijskoj fazi 210 mg ili 140 mg u 0. tjednu (1. dan), 1. tjednu i 2. tjednu,
English: • tiredness
Croatian: • proljev
English: During the 12-week placebo-controlled trial period in plaque psoriasis, infections were reported in 25.4% of patients treated with Kyntheum compared with 23.4% of patients treated with placebo.
Croatian: prijavljene su infekcije u 25,4% bolesnika koji su primali Kyntheum u usporedbi sa 23,4% bolesnika koji su primali placebo.
English: Teл.
Croatian: Ltd.
English: • diarrhoea
Croatian: • umor
English: Tel.: +48 22 244 18 40
Croatian: LEO Pharma Sp. z o.o. Tel.: +48 22 244 18 40
English: Do not place your finger on the plunger while inserting the needle.
Croatian: Nemojte držati prst na klipu pri umetanju igle.
English: LEO Pharma B.V. Tel: +31 205104141
Croatian: Tel: +31 205104141
English: At Week 12, patients in the ustekinumab group continued to receive ustekinumab and then were switched to Kyntheum 210 mg every 2 weeks at Week 52.
Croatian: a zatim su u 52. tjednu počeli primati Kyntheum 210 mg svaka 2 tjedna.
English: Posology
Croatian: Učestalost
English: This is in case the syringe is broken.
Croatian: Štrcaljka se možda oštetila.
English: Brodalumab is a monoclonal antibody, a specialised type of protein that recognises and attaches to certain proteins in the body.
Croatian: posebna vrsta bjelančevine koja prepoznaje određene bjelančevine u tijelu i veže se za njih.
English: Frequency Adverse Reaction
Croatian: Manje često konjunktivitis
English: Used needle
Croatian: Upotrijebljena igla
English: Plunger
Croatian: Imunogenost
English: Used syringe barrel
Croatian: Upotrijebljeno tijelo štrcaljke
English: E.J.
Croatian: RMP-a.
English: Step 1: Preparing A. Remove the Kyntheum pre-filled syringe from the box
Croatian: PRILOG I. SAŽETAK OPISA SVOJSTAVA LIJEKA
English: Renal or hepatic impairment
Croatian: Oštećenje funkcije bubrega ili jetre
English: days.
Croatian: DJECE
English: 30 sachets + 1 mixing bottle + 30 single-use oral syringes + 1 screw cap with syringe-port capability
Croatian: 30 vrećica + 1 bočica za miješanje + 30 štrcaljki za usta za jednokratnu uporabu + 1 zatvarač s navojem u koji se može umetnuti štrcaljka
English: Powder for oral suspension
Croatian: Prašak za oralnu suspenziju
English: Oral use sachet (PET/OPA/alu/LDPE)
Croatian: Vrećica (PET/OPA/alu/LDP E)
English: MA (EU) number (Invented) name Strength
Croatian: Broj (EU) odobrenja (Zaštićeno) ime
English: ≥ 2.0 IU***
Croatian: ≥ 2,0 IJ***/ml
English: 103.1 - 105.1 TCID50*
Croatian: 103,1 -105,1 TCID50/ml
English: Invente d name
Croatian: Izmišljeno ime
English: Pharmaceutic al form
Croatian: Jačina Farmaceutski oblik
English: Rabies virus, strain SAD Vnukovo-32
Croatian: Virus bjesnoće, soj SAD Vnukovo-32
English: --1 Lyophilisate (live attenuated) Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15
Croatian: --1 Liofilizat (živi atenuirani) Pseći parainfluenca virus tip 2, soj CPiV-2-Bio 15
English: EU (MA) number
Croatian: EU broj odobrenja
English: Content Package size
Croatian: Put primjene Pakovanje Sastav Veličina pakovanja
English: Target specie s
Croatian: Ciljne vrste životinja
English: Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091
Croatian: Leptospira kirschneri serogrupa Grippotyphosa serovar Grippotyphosa, soj MSLB 1091
English: Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088
Croatian: Leptospira interrogans serogrupa Australis serovar Bratislava, soj MSLB 1088
English: ** Antibody micro agglutination-lytic reaction.
Croatian: * 50% infektivne doze kulture tkiva ** mikro aglutinacijska-litička reakcija antitijela *** internacionalnih jedinica
English: Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089
Croatian: Suspenzija(inaktivirana) Leptospira interrogans serogrupa Icterohaemorrhagiae serovar Icterohaemorrhagiae, soj MSLB 1089
English: Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090
Croatian: Leptospira interrogans serogrupa Canicola serovar Canicola, soj MSLB 1090
English: Packagin g
Croatian: Liofilzat:
English: l Suspension (inactivated)
Croatian: Liofilizat i suspenzija, za suspenziju za injekciju
English: Strengt h
Croatian: Liofilizat:
English: EU/1/11/671/001
Croatian: EU/1/11/671/001 Xiapex
English: powder: 3 ml solvent: 5 ml
Croatian: prašak: 3 ml otopina: 5 ml
English: 1 vial + 1 vial
Croatian: 1 bočica + 1 bočica
English: Intralesional use powder: vial (glass) solvent: vial (glass)
Croatian: U ozljedu prašak: bočica (staklo) otopina: bočica (staklo)
English: Xiapex
Croatian: Doza
English: Package size
Croatian: Veličina pakovanja
English: 0.9 mg Powder and solvent for solution for injection
Croatian: Prašak i otapalo za otopinu za injekciju
English: The company wanted the authorisation to be recognised in other EU Member States (the ‘concerned Member States', in this instance Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom).
Croatian: Tvrtka je zatražila priznavanje odobrenja u drugim državama članicama EU-a ("državama članicama u postupku", u ovom slučaju Austriji, Belgiji, Bugarskoj, Hrvatskoj, Cipru, Češkoj Republici, Estoniji, Finskoj, Njemačkoj, Grčkoj, Islandu, Irskoj, Italiji, Latviji, Litvi, Nizozemskoj, Poljskoj, Portugalu, Rumunjskoj, Slovačkoj, Sloveniji, Švedskoj i Ujedinjenoj Kraljevini).
English: Outcome of a procedure under Article 33(4) of Directive 2001/82/EC, as amended
Croatian: Ishod postupka u skladu s člankom 33. stavkom 4. Direktive 2001/82/EZ, kako je izmijenjena
English: Veterinary Medicines Division
Croatian: Odjel za veterinarsko-medicinske proizvode
English: The European Commission issued a decision on 28 August 2015.
Croatian: Europska komisija donijela je odluku dana 28. kolovoza 2015.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28 August 2015
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28. kolovoza 2015.
English: What are the conclusions of the CVMP?
Croatian: Koje je zaključke donio CVMP?
English: However, the Member States were not able to reach an agreement and the National Food Chain Safety Office of Hungary referred the matter to the CVMP for arbitration on 24 October 2014.
Croatian: Međutim, države članice nisu bile u stanju postići dogovor, te je Nacionalna agencija za sigurnost prehrambenog lanca Mađarske 24. listopada 2014. uputila predmet CVMP-u na arbitražu.
English: Duration of immunity was established for both serotypes (1 and 2) up to 16 weeks after vaccination according to the results of relevant challenge studies.
Croatian: Trajanje imunosti utvrđeno je za oba serotipa (1 i 2) do 16 tjedana nakon cijepljenja u skladu s rezultatima relevantnima za ispitivanja izazova.
English: On 3 June 2015, the European Medicines Agency (the Agency) completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Coglapix suspension for injection for pigs.
Croatian: Dana 3. lipnja 2015., Europska agencija za lijekove završila je arbitražni postupak nastavno na neslaganje država članica Europske unije (EU) u vezi s odobrenjem VMP-a Coglapix za injekciju za svinje.
English: The vaccine is intended for active immunisation of pigs against pleuropneumonia caused by A. pleuropneumoniae serotypes 1 and 2, in order to reduce the clinical signs and lung lesions associated with the disease.
Croatian: Cjepivo je predviđeno za aktivnu imunizaciju svinja protiv pleuropnemonije uzrokovane bakterijom A. pleuropneumoniae serotipova 1 i 2, kako bio se smanjili klinički znakovi i lezije pluća povezane s bolesti.
English: Therefore, based on evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that the benefits of Coglapix outweigh its risks, and recommended that the marketing authorisation be granted in all concerned Member States.
Croatian: Stoga, na osnovu ocjene trenutno dostupnih podataka i znanstvenih rasprava unutar Odbora, CVMP je zaključio kako koristi VMP-a Coglapix nadmašuju s njim povezane rizike i preporučio je izdavanje odobrenja za stavljanje VMP-a u promet u svim državama članicama u postupku.
English: The product information for Coglapix in Hungary should also be amended.
Croatian: Informacije o VMP-u Coglapix izdane u Mađarskoj trebaju biti također izmijenjene.
English: The vaccine contains five formaldehyde-inactivated strains of Actinobacillus pleuropneumoniae.
Croatian: Cjepivo sadrži pet sojeva s inaktiviranim formaldehidom bakterije Actinobacillus pleuropneumoniae.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Coglapix outweigh its risks, and the marketing authorisation granted in Hungary can be recognised in other Member States of the EU (see below).
Croatian: Odbor za veterinarsko-medicinske lijekove (CVMP) pri Agenciji zaključio je da koristi VMP-a Coglapix nadmašuju s njim povezane rizike, te da se odobrenje za stavljanje VMP-a u promet izdano u Mađarskoj može priznati i u drugom državama članicama EU-a (pogledajte niže u tekstu).
English: What is Coglapix suspension for injection for pigs?
Croatian: Što je Coglapix suspenzija za injekciju za svinje?
English: Based on the data presented it was concluded that following vaccination of pigs with Coglapix reduction of clinical signs and lung lesions associated with the disease has been demonstrated in laboratory efficacy studies, although some concerns on the statistical significance of the results still remain.
Croatian: Na temelju dostavljenih podataka, zaključeno je da nakon cijepljenja svinja VMP-om Coglapix smanjenje kliničkih znakova i lezija pluća povezano s bolesti utvrđeno u laboratorijskim ispitivanjima djelotvornosti, iako su pojedini zabrinutosti o statističkom značaju rezultata ostale otvorene.
English: Why was Coglapix suspension for injection for pigs reviewed?
Croatian: Zašto je Coglapix suspenzija za injekciju za svinje pregledana?
English: The grounds for the referral were concerns raised by Italy that the efficacy of Coglapix has not been adequately demonstrated, that the benefit of the vaccine under practical conditions of use has not been demonstrated and that the results obtained from duration of immunity studies were inconsistent.
Croatian: Razlozi za postupak upućivanja bile su zabrinutosti koje je iznijela Italija vezane uz primjereno utvrđivanje djelotvornosti VMP-a Coglapix, dokazivanje koristi cjepiva u praktičnim uvjetima primjene i nekonzistentnost rezultata prikupljenih tijekom trajanja ispitivanja imunosti.
English: Ceva-Phylaxia Veterinary Biologicals Co. Ltd. submitted an application for Coglapix for mutual recognition on the basis of the initial authorisation granted by Hungary.
Croatian: Ltd. dostavila je zahtjev za VMP Coglapix za međusobno priznavanje na osnovu prvotnoga odobrenja izdanog u Mađarskoj.
English: Coglapix is an inactivated bacterial vaccine against porcine actinobacillosis.
Croatian: Coglapix je inaktivirano bakterijsko cjepovo protiv svinjske aktinobaciloze.
English: The CVMP also recommended that the product information for the medicine in Hungary be amended.
Croatian: CVMP je također preporučio dopunu informacija o VMP-u u Mađarskoj.
English: Hence, the relevant sections of the Summary of Product Characteristics and package leaflet should be amended in order to reflect this.
Croatian: Stoga, relevantne dijelove sažetka opisa svojstava VMP-a i upute o VMP-u treba izmijeniti kako bi jasno prikazivali ove zaključke.
English: Content (concentration) Pack size
Croatian: Sastav (koncentracija)
English: 10 vials (multidose: 10 doses)
Croatian: 5,0 ml (1 doza = 0,5 ml) 10 bočica (višedoznih:
English: MA (EU) number (Invented) name
Croatian: Broj EU odobrenja
English: 10 vials (monodose)
Croatian: 10 doza)
English: Route of administration
Croatian: Put primjene Unutarnje pakovanje
English: What is Ivemend and what is it used for?
Croatian: Što je Ivemend i za što se koristi?
English: This means that it is converted to aprepitant in the body.
Croatian: To znači da se u tijelu pretvara u aprepitant.
English: Aprepitant has been authorised in the European Union (EU) as Emend since 2003.
Croatian: Aprepitant je od 2003. odobren u Europskoj uniji (EU) pod nazivom Emend.
English: What measures are being taken to ensure the safe and effective use of Ivemend?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Ivemend?
English: In children it may be given on the first day or on multiple days through a tube inserted into a large vein near the heart.
Croatian: U djece se može davati prvoga dana ili više dana kroz cjevčicu koja se uvodi u veliku venu u blizini srca.
English: Aprepitant is a neurokinin 1 (NK1) receptor antagonist.
Croatian: Aprepitant je antagonist receptora neurokinina 1 (NK1).
English: What are the risks associated with Ivemend?
Croatian: Koji su rizici povezani s lijekom Ivemend?
English: Further information on Ivemend can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Ivemend nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Ovaj pregled informacija posljednji je put ažuriran u 5. 2018.
English: Other information about Ivemend
Croatian: Ostale informacije o lijeku Ivemend
English: Why is Ivemend authorised in the EU?
Croatian: Zašto je lijek Ivemend odobren u EU-u?
English: How is Ivemend used?
Croatian: Kako se Ivemend koristi?
English: An overview of Ivemend and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Ivemend i zašto je odobren u EU-u
English: By blocking these receptors, Ivemend can prevent nausea and vomiting, which often happens during and after chemotherapy.
Croatian: Blokiranjem tih receptora Ivemend može spriječiti mučninu i povraćanje, koji se često javljaju tijekom i nakon kemoterapije.
English: As for all medicines, data on the use of Ivemend are continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Ivemend kontinuirano se prate.
English: It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting.
Croatian: Upotrebljava se u odraslih i u djece starije od 6 mjeseci koji primaju kemoterapiju za koju se zna da uzrokuje umjerenu ili ozbiljnu mučninu i povraćanje.
English: In adults, Ivemend is given as a slow infusion into a vein on the first day of chemotherapy.
Croatian: U odraslih se Ivemend daje u obliku spore infuzije u venu prvoga dana kemoterapije.
English: Ivemend received a marketing authorisation valid throughout the EU on 11 January 2008.
Croatian: Lijek Ivemend je dobio odobrenje za stavljanje u promet koje je na snazi na prostoru EU-a od 11. siječnja 2008.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivemend have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Ivemend nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: The most common side effects with Ivemend (seen in between 1 and 10 patients in 100) are increased liver enzymes, headache, hiccups, constipation, dyspepsia (heartburn), loss of appetite and fatigue (weakness or tiredness).
Croatian: Najčešće nuspojave povezane s lijekom Ivemend (mogu se javiti u 1 do 10 na 100 bolesnika) jesu povišeni jetreni enzimi, glavobolja, štucanje, zatvor, dispepsija (žgaravica), gubitak apetita i iscrpljenost (slabost ili umor).
English: It contains the active substance fosaprepitant.
Croatian: Sadrži djelatnu tvar fosaprepitant.
English: The European Medicines Agency therefore decided that Ivemend's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Ivemend nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: Side effects reported with Ivemend are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Ivemend pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: A main study in 2,000 patients with cancer showed that Ivemend was as effective as a Emend another medicine approved for preventing nausea and vomiting.
Croatian: Glavnim ispitivanjem provedenim na 2 000 bolesnika koji imaju rak utvrđeno je da je Ivemend jednako djelotvoran kao Emend, drugi lijek odobren za sprečavanje mučnine i povraćanja.
English: For more information about using Ivemend, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Ivemend pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Ivemend must always be given together with other medicines that prevent nausea and vomiting, including a corticosteroid (such as dexamethasone) and a ‘5HT3 antagonist' (such as ondansetron).
Croatian: Ivemend se uvijek mora davati s drugim lijekovima koji sprečavaju mučninu i povraćanje, uključujući kortikosteroid (kao što je deksametazon) i „antagonist 5-HT3” (kao što je ondanzetron).
English: It stops a chemical in the body called ‘substance P' from attaching to the NK1 receptors.
Croatian: Sprečava vezanje kemijske tvari u tijelu naziva tvar P na receptore NK1.
English: Ivemend must not be used at the same time as pimozide (used to treat mental illness), terfenadine and astemizole (used to treat allergy symptoms) and cisapride (used to relieve certain stomach problems).
Croatian: Ivemend se ne smije primjenjivati istodobno s pimozidom (upotrebljava se za liječenje mentalnih bolesti), terfenadinom i astemizolom (upotrebljavaju se za liječenje alergijskih simptoma) ni cisapridom (upotrebljava se za ublažavanje određenih želučanih problema).
English: Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines.
Croatian: Ivemend je lijek koji se upotrebljava za sprečavanje mučnine (osjećaja slabosti) i povraćanja uzrokovanih kemoterapijskim lijekovima protiv raka.
English: When substance P attaches to these receptors, it causes nausea and vomiting.
Croatian: Kada se tvar P veže na te receptore, uzrokuje mučninu i povraćanje.
English: The active substance in Ivemend, fosaprepitant, is a ‘prodrug' of aprepitant.
Croatian: Djelatna tvar u lijeku Ivemend, fosaprepitant, „prolijek” je aprepitanta.
English: What benefits of Ivemend have been shown in studies?
Croatian: Koje su koristi od lijeka Ivemend utvrđene u ispitivanjima?
English: How does Ivemend work?
Croatian: Kako djeluje Ivemend?
English: Around 72% of patients treated with either medicine did not have any nausea or vomiting over the five days after receiving chemotherapy.
Croatian: liječenih jednim od tih dvaju lijekova nije osjećalo mučninu niti je povraćalo tijekom pet dana nakon primanja kemoterapije.
English: For the full list of side effects reported with Ivemend, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Ivemend potražite u uputi o lijeku.
English: A main study showed that Ivemend was as effective as Emend at preventing nausea and vomiting in patients undergoing chemotherapy and its side effects are considered to be manageable.
Croatian: Glavnim ispitivanjem utvrđeno je da je kod sprečavanja mučnine i povraćanja u bolesnika koji primaju kemoterapiju
English: _ _ 1 Whole virion non-adjuvanted influenza vaccine, inactivated, containing antigen of *: A/Vietnam/1203/2004 (H5N1) 7.5 micrograms** per 0.5 ml dose * propagated in Vero cells (continuous cell line of mammalian origin) ** expressed in micrograms hemagglutinin
Croatian: *: A / Vietnam / 1203/2004 (H5N1) 7,5 mikrograma ** po 0,5 ml doze * razmnoženi u Vero stanicama (kontinuirana stanična linija podrijetla sisavaca) ** izraženo u mikrogramima hemaglutinina